Back to results
US 2021/0261932 A1Published application
Crispr-cas enzymes with enhanced on-target activity
AssigneeThe General Hospital Corporation
InventorsBenjamin Kleinstiver, Russell T. Walton
Life of this patent
Estimating the term…
Abstract
Engineered versions of Streptococcus pyogenes Cas9 (SpCas9) and SpCas9 variants that have improved on-target editing capabilities, and methods of use thereof.
Claims35
An isolated Streptococcus pyogenes Cas9 (SpCas9) protein, with mutations at one, two, three, four, five, or more of the positions shown in Table 1, 2, or 3, wherein if only one mutation is present, the mutation is not G1218R;
- L1111R;
- A1322R:
- D1332K;
- N394K;
- R221K;
- L1245V;
- E1243K;
- or E1253K.
5 more elements
Dependencies are inferred from the claim text.